Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection

{ 'indexed': {'date-parts': [[2023, 6, 24]], 'date-time': '2023-06-24T04:22:09Z', 'timestamp': 1687580529995}, 'reference-count': 69, 'publisher': 'Elsevier BV', 'license': [ { 'start': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T00:00:00Z', 'timestamp': 1685577600000}, 'content-version': 'tdm', 'delay-in-days': 0, 'URL': 'https://www.elsevier.com/tdm/userlicense/1.0/'}, { 'start': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T00:00:00Z', 'timestamp': 1685577600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-017'}, { 'start': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T00:00:00Z', 'timestamp': 1685577600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-037'}, { 'start': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T00:00:00Z', 'timestamp': 1685577600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-012'}, { 'start': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T00:00:00Z', 'timestamp': 1685577600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-029'}, { 'start': { 'date-parts': [[2023, 6, 1]], 'date-time': '2023-06-01T00:00:00Z', 'timestamp': 1685577600000}, 'content-version': 'stm-asf', 'delay-in-days': 0, 'URL': 'https://doi.org/10.15223/policy-004'}], 'content-domain': {'domain': ['elsevier.com', 'sciencedirect.com'], 'crossmark-restriction': True}, 'published-print': {'date-parts': [[2023, 6]]}, 'DOI': '10.1016/j.antiviral.2023.105655', 'type': 'journal-article', 'created': {'date-parts': [[2023, 6, 23]], 'date-time': '2023-06-23T05:09:03Z', 'timestamp': 1687496943000}, 'page': '105655', 'update-policy': 'http://dx.doi.org/10.1016/elsevier_cm_policy', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 infection', 'prefix': '10.1016', 'author': [ { 'ORCID': 'http://orcid.org/0000-0003-2538-7339', 'authenticated-orcid': False, 'given': 'Rafaela', 'family': 'Milan Bonotto', 'sequence': 'first', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-6996-4831', 'authenticated-orcid': False, 'given': 'Ana', 'family': 'Mitrović', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-3370-4587', 'authenticated-orcid': False, 'given': 'Izidor', 'family': 'Sosič', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-2025-9445', 'authenticated-orcid': False, 'given': 'Pamela', 'family': 'Martinez-Orellana', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0001-7417-3498', 'authenticated-orcid': False, 'given': 'Federica', 'family': 'Dattola', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-9678-3083', 'authenticated-orcid': False, 'given': 'Stanislav', 'family': 'Gobec', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-4228-3518', 'authenticated-orcid': False, 'given': 'Janko', 'family': 'Kos', 'sequence': 'additional', 'affiliation': []}, { 'ORCID': 'http://orcid.org/0000-0002-8903-8202', 'authenticated-orcid': False, 'given': 'Alessandro', 'family': 'Marcello', 'sequence': 'additional', 'affiliation': []}], 'member': '78', 'reference': [ { 'key': '10.1016/j.antiviral.2023.105655_bib1', 'doi-asserted-by': 'crossref', 'first-page': '2956', 'DOI': '10.1021/acs.jmedchem.1c01494', 'article-title': 'Potent anti-SARS-CoV-2 activity by the natural product gallinamide A ' 'and analogues via inhibition of cathepsin L', 'volume': '65', 'author': 'Ashhurst', 'year': '2022', 'journal-title': 'J. Med. Chem.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib2', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.isci.2022.105316', 'article-title': 'Identification and differential usage of a host metalloproteinase entry ' 'pathway by SARS-CoV-2 Delta and Omicron', 'volume': '25', 'author': 'Benlarbi', 'year': '2022', 'journal-title': 'iScience'}, { 'key': '10.1016/j.antiviral.2023.105655_bib3', 'doi-asserted-by': 'crossref', 'first-page': '1131', 'DOI': '10.1002/pro.4073', 'article-title': 'Multiple sites on SARS-CoV-2 spike protein are susceptible to ' 'proteolysis by cathepsins B, K, L, S, and V', 'volume': '30', 'author': 'Bollavaram', 'year': '2021', 'journal-title': 'Protein Sci.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib4', 'doi-asserted-by': 'crossref', 'first-page': 'e2', 'DOI': '10.1016/S2666-5247(20)30008-2', 'article-title': 'SARS-CoV-2 cellular tropism', 'volume': '1', 'author': 'Cagno', 'year': '2020', 'journal-title': 'The Lancet Microbe'}, { 'key': '10.1016/j.antiviral.2023.105655_bib5', 'doi-asserted-by': 'crossref', 'first-page': '1643', 'DOI': '10.1126/science.1110656', 'article-title': 'Endosomal proteolysis of the Ebola virus glycoprotein is necessary for ' 'infection', 'volume': '308', 'author': 'Chandran', 'year': '2005', 'journal-title': 'Science (New York, N.Y.)'}, { 'key': '10.1016/j.antiviral.2023.105655_bib6', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s12985-021-01624-x', 'article-title': 'Keep out! SARS-CoV-2 entry inhibitors: their role and utility as ' 'COVID-19 therapeutics', 'volume': '18', 'author': 'Chitsike', 'year': '2021', 'journal-title': 'Virol. J.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib7', 'series-title': 'Evaluation of Enzyme Inhibitors in Drug Discovery: a Guide for Medicinal ' 'Chemists and Pharmacologists', 'author': 'Copeland', 'year': '2005'}, {'key': '10.1016/j.antiviral.2023.105655_bib8', 'author': 'CoVariants'}, { 'key': '10.1016/j.antiviral.2023.105655_bib9', 'series-title': 'A Review of Small Molecule Inhibitors and Functional Probes of Human ' 'Cathepsin L', 'author': 'Dana', 'year': '2020'}, { 'key': '10.1016/j.antiviral.2023.105655_bib10', 'doi-asserted-by': 'crossref', 'first-page': '391', 'DOI': '10.1016/j.virol.2008.02.019', 'article-title': 'Role of endocytosis and cathepsin-mediated activation in Nipah virus ' 'entry', 'volume': '375', 'author': 'Diederich', 'year': '2008', 'journal-title': 'Virology'}, { 'key': '10.1016/j.antiviral.2023.105655_bib11', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.cbi.2022.109796', 'article-title': 'Cathepsin B is a potential therapeutic target for coronavirus disease ' '2019 patients with lung adenocarcinoma', 'volume': '353', 'author': 'Ding', 'year': '2022', 'journal-title': 'Chem. Biol. Interact.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib12', 'doi-asserted-by': 'crossref', 'first-page': '340', 'DOI': '10.1038/d41586-021-00958-4', 'article-title': 'The race for antiviral drugs to beat COVID — and the next pandemic', 'volume': '592', 'author': 'Dolgin', 'year': '2021', 'journal-title': 'Nature'}, { 'key': '10.1016/j.antiviral.2023.105655_bib13', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41392-022-00903-5', 'article-title': 'Omicron adopts a different strategy from Delta and other variants to ' 'adapt to host', 'volume': '7', 'author': 'Du', 'year': '2022', 'journal-title': 'Signal Transduct. Targeted Ther.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib14', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.jbc.2021.100847', 'article-title': 'Role of host factors in SARS-CoV-2 entry', 'volume': '297', 'author': 'Evans', 'year': '2021', 'journal-title': 'J. Biol. Chem.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib15', 'doi-asserted-by': 'crossref', 'DOI': '10.1186/s12985-022-01887-y', 'article-title': "As the virus evolves, so too must we: a drug developer's perspective", 'volume': '19', 'author': 'Fang', 'year': '2022', 'journal-title': 'Virol. J.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib16', 'doi-asserted-by': 'crossref', 'DOI': '10.3389/fcimb.2020.589505', 'article-title': 'Cathepsin L in COVID-19: from pharmacological evidences to genetics', 'volume': '10', 'author': 'Gomes', 'year': '2020', 'journal-title': 'Front. Cell. Infect. Microbiol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib17', 'doi-asserted-by': 'crossref', 'first-page': '305', 'DOI': '10.1056/NEJMoa2116846', 'article-title': 'Early remdesivir to prevent progression to severe covid-19 in ' 'outpatients', 'volume': '386', 'author': 'Gottlieb', 'year': '2022', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib18', 'doi-asserted-by': 'crossref', 'first-page': '271', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a ' 'clinically proven protease inhibitor', 'volume': '181', 'author': 'Hoffmann', 'year': '2020', 'journal-title': 'Cell'}, { 'key': '10.1016/j.antiviral.2023.105655_bib19', 'doi-asserted-by': 'crossref', 'first-page': '2275', 'DOI': '10.1080/22221751.2022.2117098', 'article-title': 'Spike mutations contributing to the altered entry preference of ' 'SARS-CoV-2 omicron BA.1 and BA.2', 'volume': '11', 'author': 'Hu', 'year': '2022', 'journal-title': 'Emerg. Microb. Infect.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib20', 'doi-asserted-by': 'crossref', 'first-page': '715', 'DOI': '10.1038/s41586-022-04479-6', 'article-title': 'SARS-CoV-2 Omicron variant replication in human bronchus and lung ex ' 'vivo', 'volume': '603', 'author': 'Hui', 'year': '2022', 'journal-title': 'Nature'}, { 'key': '10.1016/j.antiviral.2023.105655_bib21', 'doi-asserted-by': 'crossref', 'first-page': '89', 'DOI': '10.1056/NEJMc2214302', 'article-title': 'Efficacy of antiviral agents against omicron subvariants BQ.1.1 and XBB', 'volume': '388', 'author': 'Imai', 'year': '2023', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib22', 'doi-asserted-by': 'crossref', 'first-page': '3', 'DOI': '10.1038/s41580-021-00418-x', 'article-title': 'Mechanisms of SARS-CoV-2 entry into cells', 'volume': '23', 'author': 'Jackson', 'year': '2022', 'journal-title': 'Nat. Rev. Mol. Cell Biol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib23', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.isci.2020.101212', 'article-title': 'Proteolytic cleavage of the SARS-CoV-2 spike protein and the role of ' 'the novel S1/S2 site', 'volume': '23', 'author': 'Jaimes', 'year': '2020', 'journal-title': 'iScience'}, { 'key': '10.1016/j.antiviral.2023.105655_bib24', 'doi-asserted-by': 'crossref', 'first-page': '509', 'DOI': '10.1056/NEJMoa2116044', 'article-title': 'Molnupiravir for oral treatment of covid-19 in nonhospitalized patients', 'volume': '386', 'author': 'Jayk Bernal', 'year': '2022', 'journal-title': 'N. Engl. J. Med.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib25', 'doi-asserted-by': 'crossref', 'first-page': '6', 'DOI': '10.1016/S0014-5793(99)01107-2', 'article-title': 'Structure based development of novel specific inhibitors for cathepsin ' 'L and cathepsin S in vitro and in vivo', 'volume': '458', 'author': 'Katunuma', 'year': '1999', 'journal-title': 'FEBS (Fed. Eur. Biochem. Soc.) Lett.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib26', 'doi-asserted-by': 'crossref', 'first-page': '712', 'DOI': '10.1128/JVI.01933-08', 'article-title': 'Protease-mediated entry via the endosome of human coronavirus 229E', 'volume': '83', 'author': 'Kawase', 'year': '2009', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib27', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41467-020-20542-0', 'article-title': 'Mechanism of SARS-CoV-2 polymerase stalling by remdesivir', 'volume': '12', 'author': 'Kokic', 'year': '2021', 'journal-title': 'Nat. Commun.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib28', 'doi-asserted-by': 'crossref', 'first-page': '1355', 'DOI': '10.4155/fmc.14.73', 'article-title': 'The current stage of cathepsin B inhibitors as potential anticancer ' 'agents', 'volume': '6', 'author': 'Kos', 'year': '2014', 'journal-title': 'Future Med. Chem.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib29', 'doi-asserted-by': 'crossref', 'first-page': '103', 'DOI': '10.1016/j.yexcr.2004.12.006', 'article-title': 'Carboxypeptidases cathepsins X and B display distinct protein profile ' 'in human cells and tissues', 'volume': '306', 'author': 'Kos', 'year': '2005', 'journal-title': 'Exp. Cell Res.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib30', 'doi-asserted-by': 'crossref', 'DOI': '10.1128/JVI.00543-20', 'article-title': 'Isolation and full-length genome characterization of SARS-CoV-2 from ' 'COVID-19 cases in northern Italy', 'volume': '94', 'author': 'Licastro', 'year': '2020', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib31', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.pharmthera.2020.107587', 'article-title': 'Cathepsin L-selective inhibitors: a potentially promising treatment for ' 'COVID-19 patients', 'volume': '213', 'author': 'Liu', 'year': '2020', 'journal-title': 'Pharmacol. Therapeut.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib32', 'first-page': '1', 'article-title': 'Paxlovid: mechanism of action, synthesis, and in silico study', 'volume': '2022', 'author': 'Marzi', 'year': '2022', 'journal-title': 'BioMed Res. Int.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib33', 'doi-asserted-by': 'crossref', 'first-page': '8', 'DOI': '10.1016/j.slasd.2021.10.012', 'article-title': 'Identification of potent small molecule inhibitors of SARS-CoV-2 entry', 'volume': '27', 'author': 'Mediouni', 'year': '2022', 'journal-title': 'SLAS Discov.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib34', 'doi-asserted-by': 'crossref', 'first-page': '642', 'DOI': '10.1021/acschembio.0c00875', 'article-title': 'A clinical-stage cysteine protease inhibitor blocks SARS-CoV-2 ' 'infection of human and monkey cells', 'volume': '16', 'author': 'Mellott', 'year': '2021', 'journal-title': 'ACS Chem. Biol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib35', 'doi-asserted-by': 'crossref', 'first-page': '706', 'DOI': '10.1038/s41586-022-04474-x', 'article-title': 'Altered TMPRSS2 usage by SARS-CoV-2 Omicron impacts infectivity and ' 'fusogenicity', 'volume': '603', 'author': 'Meng', 'year': '2022', 'journal-title': 'Nature'}, { 'key': '10.1016/j.antiviral.2023.105655_bib36', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/v14061157', 'article-title': 'Virucidal activity of the pyridobenzothiazolone derivative HeE1-17Y ' 'against enveloped RNA viruses', 'volume': '14', 'author': 'Milan Bonotto', 'year': '2022', 'journal-title': 'Viruses'}, { 'key': '10.1016/j.antiviral.2023.105655_bib37', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.antiviral.2021.105055', 'article-title': 'Combined in silico and in vitro approaches identified the antipsychotic ' 'drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and ' 'HCoV-OC43 inhibitors', 'volume': '189', 'author': 'Milani', 'year': '2021', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib38', 'doi-asserted-by': 'crossref', 'first-page': '19027', 'DOI': '10.18632/oncotarget.3699', 'article-title': 'Nitroxoline impairs tumor progression in vitro and in vivo by ' 'regulating cathepsin B activity', 'volume': '6', 'author': 'Mirković', 'year': '2015', 'journal-title': 'Oncotarget'}, { 'key': '10.1016/j.antiviral.2023.105655_bib39', 'doi-asserted-by': 'crossref', 'first-page': '1351', 'DOI': '10.1002/cmdc.201100098', 'article-title': 'Novel mechanism of cathepsin B inhibition by antibiotic nitroxoline and ' 'related compounds', 'volume': '6', 'author': 'Mirković', 'year': '2011', 'journal-title': 'ChemMedChem'}, { 'key': '10.1016/j.antiviral.2023.105655_bib40', 'doi-asserted-by': 'crossref', 'first-page': '165', 'DOI': '10.1515/hsz-2015-0236', 'article-title': 'Inhibition of endopeptidase and exopeptidase activity of cathepsin B ' 'impairs extracellular matrix degradation and tumour invasion', 'volume': '397', 'author': 'Mitrović', 'year': '2016', 'journal-title': 'Biol. Chem.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib41', 'doi-asserted-by': 'crossref', 'first-page': '4667', 'DOI': '10.1016/j.csbj.2022.08.046', 'article-title': 'New inhibitors of cathepsin V impair tumor cell proliferation and ' 'elastin degradation and increase immune cell cytotoxicity', 'volume': '20', 'author': 'Mitrović', 'year': '2022', 'journal-title': 'Comput. Struct. Biotechnol. J.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib42', 'doi-asserted-by': 'crossref', 'first-page': '59136', 'DOI': '10.18632/oncotarget.19296', 'article-title': 'Addition of 2-(ethylamino)acetonitrile group to nitroxoline results in ' 'significantly improved anti-tumor activityin vitroandin vivo', 'volume': '8', 'author': 'Mitrović', 'year': '2017', 'journal-title': 'Oncotarget'}, { 'key': '10.1016/j.antiviral.2023.105655_bib43', 'first-page': '476', 'article-title': 'Clinical pharmacokinetics of nitroxoline', 'volume': '17', 'author': 'Mrhar', 'year': '1979', 'journal-title': 'Int. J. Clin. Pharmacol. Biopharm.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib44', 'doi-asserted-by': 'crossref', 'first-page': '628', 'DOI': '10.1186/s12879-014-0628-7', 'article-title': "Review of the literature and individual patients' data meta-analysis on " 'efficacy and tolerance of nitroxoline in the treatment of uncomplicated ' 'urinary tract infections', 'volume': '14', 'author': 'Naber', 'year': '2014', 'journal-title': 'BMC Infect. Dis.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib45', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.ppat.1009212', 'article-title': 'Hydroxychloroquine-mediated inhibition of SARS-CoV-2 entry is ' 'attenuated by TMPRSS2', 'volume': '17', 'author': 'Ou', 'year': '2021', 'journal-title': 'PLoS Pathog.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib46', 'doi-asserted-by': 'crossref', 'DOI': '10.1038/s41467-020-15562-9', 'article-title': 'Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and ' 'its immune cross-reactivity with SARS-CoV', 'volume': '11', 'author': 'Ou', 'year': '2020', 'journal-title': 'Nat. Commun.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib47', 'doi-asserted-by': 'crossref', 'DOI': '10.1371/journal.pcbi.1008461', 'article-title': 'Targeting TMPRSS2 and Cathepsin B/L together may be synergistic against ' 'SARS-CoV-2 infection', 'volume': '16', 'author': 'Padmanabhan', 'year': '2020', 'journal-title': 'PLoS Comput. Biol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib48', 'doi-asserted-by': 'crossref', 'first-page': '1', 'DOI': '10.1371/journal.ppat.1009013', 'article-title': 'The role of cysteine peptidases in coronavirus cell entry and ' 'replication: the therapeutic potential of cathepsin inhibitors', 'volume': '16', 'author': 'Pišlar', 'year': '2020', 'journal-title': 'PLoS Pathog.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib49', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/v13050808', 'article-title': 'Inhibitors of protein glycosylation are active against the coronavirus ' 'severe acute respiratory syndrome coronavirus SARS-CoV-2', 'volume': '13', 'author': 'Rajasekharan', 'year': '2021', 'journal-title': 'Viruses'}, { 'key': '10.1016/j.antiviral.2023.105655_bib50', 'doi-asserted-by': 'crossref', 'first-page': '235', 'DOI': '10.1016/j.vetmic.2008.05.019', 'article-title': 'Differential role for low pH and cathepsin-mediated cleavage of the ' 'viral spike protein during entry of serotype II feline coronaviruses', 'volume': '132', 'author': 'Regan', 'year': '2008', 'journal-title': 'Vet. Microbiol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib51', 'doi-asserted-by': 'crossref', 'DOI': '10.1016/j.isci.2021.102420', 'article-title': 'Cell-type-resolved quantitative proteomics map of interferon response ' 'against SARS-CoV-2', 'volume': '24', 'author': 'Saccon', 'year': '2021', 'journal-title': 'iScience'}, { 'key': '10.1016/j.antiviral.2023.105655_bib52', 'doi-asserted-by': 'crossref', 'first-page': '4174', 'DOI': '10.1128/JVI.80.8.4174-4178.2006', 'article-title': 'Role of endosomal cathepsins in entry mediated by the ebola virus ' 'glycoprotein', 'volume': '80', 'author': 'Schornberg', 'year': '2006', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib53', 'doi-asserted-by': 'crossref', 'first-page': '11727', 'DOI': '10.1073/pnas.2003138117', 'article-title': 'Cell entry mechanisms of SARS-CoV-2', 'volume': '117', 'author': 'Shang', 'year': '2020', 'journal-title': 'Proc. Natl. Acad. Sci. USA'}, { 'key': '10.1016/j.antiviral.2023.105655_bib54', 'doi-asserted-by': 'crossref', 'first-page': '12552', 'DOI': '10.1128/JVI.01890-13', 'article-title': 'Middle East respiratory syndrome coronavirus infection mediated by the ' 'transmembrane serine protease TMPRSS2', 'volume': '87', 'author': 'Shirato', 'year': '2013', 'journal-title': 'J. Virol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib55', 'doi-asserted-by': 'crossref', 'first-page': '11876', 'DOI': '10.1073/pnas.0505577102', 'article-title': 'Inhibitors of cathepsin L prevent severe acute respiratory syndrome ' 'coronavirus entry', 'volume': '102', 'author': 'Simmons', 'year': '2005', 'journal-title': 'Proc. Natl. Acad. Sci. U.S.A.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib56', 'doi-asserted-by': 'crossref', 'first-page': '605', 'DOI': '10.1016/j.antiviral.2013.09.028', 'article-title': 'Proteolytic activation of the SARS-coronavirus spike protein: cutting ' 'enzymes at the cutting edge of antiviral research', 'volume': '100', 'author': 'Simmons', 'year': '2013', 'journal-title': 'Antivir. Res.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib57', 'doi-asserted-by': 'crossref', 'first-page': '521', 'DOI': '10.1021/jm301544x', 'article-title': 'Development of new cathepsin B inhibitors: combining bioisosteric ' 'replacements and structure-based design to explore the ' 'structure-activity relationships of nitroxoline derivatives', 'volume': '56', 'author': 'Sosič', 'year': '2013', 'journal-title': 'J. Med. Chem.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib58', 'doi-asserted-by': 'crossref', 'first-page': '681', 'DOI': '10.1038/s41591-020-0868-6', 'article-title': 'SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells ' 'together with innate immune genes', 'volume': '26', 'author': 'Sungnak', 'year': '2020', 'journal-title': 'Nat. Med.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib59', 'series-title': 'Lysosomal Cysteine Proteases: More than Scavengers', 'first-page': '98', 'author': 'Turk', 'year': '2000'}, { 'key': '10.1016/j.antiviral.2023.105655_bib60', 'doi-asserted-by': 'crossref', 'first-page': '713', 'DOI': '10.1128/AAC.02147-13', 'article-title': 'Urinary concentrations and antibacterial activities of nitroxoline at ' '250 milligrams versus trimethoprim at 200 milligrams against ' 'uropathogens in healthy volunteers', 'volume': '58', 'author': 'Wagenlehner', 'year': '2014', 'journal-title': 'Antimicrob. Agents Chemother.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib62', 'doi-asserted-by': 'crossref', 'first-page': '2916', 'DOI': '10.1093/jac/dky255', 'article-title': 'Review of the pharmacokinetic properties of nitrofurantoin and ' 'nitroxoline', 'volume': '73', 'author': 'Wijma', 'year': '2018', 'journal-title': 'J. Antimicrob. Chemother.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib63', 'doi-asserted-by': 'crossref', 'first-page': '1161', 'DOI': '10.1038/s41564-022-01143-7', 'article-title': 'SARS-CoV-2 Omicron is an immune escape variant with an altered cell ' 'entry pathway', 'volume': '7', 'author': 'Willett', 'year': '2022', 'journal-title': 'Nat. Microbiol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib64', 'doi-asserted-by': 'crossref', 'first-page': '28336', 'DOI': '10.1073/pnas.2018030117', 'article-title': 'Transcriptional and proteomic insights into the host response in fatal ' 'COVID-19 cases', 'volume': '117', 'author': 'Wu', 'year': '2020', 'journal-title': 'Proc. Natl. Acad. Sci. U. S. A.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib65', 'doi-asserted-by': 'crossref', 'DOI': '10.3390/cells9071679', 'article-title': 'The ins and outs of cathepsins: physiological function and role in ' 'disease management', 'volume': '9', 'author': 'Yadati', 'year': '2020', 'journal-title': 'Cells'}, { 'key': '10.1016/j.antiviral.2023.105655_bib66', 'doi-asserted-by': 'crossref', 'first-page': '398', 'DOI': '10.3389/fcimb.2018.00398', 'article-title': 'Cellular targets for the treatment of flavivirus infections', 'volume': '8', 'author': 'Zakaria', 'year': '2018', 'journal-title': 'Front. Cell. Infect. Microbiol.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib67', 'doi-asserted-by': 'crossref', 'first-page': '277', 'DOI': '10.1080/22221751.2021.2023329', 'article-title': 'SARS-CoV-2 Omicron variant shows less efficient replication and fusion ' 'activity when compared with Delta variant in TMPRSS2-expressed cells', 'volume': '11', 'author': 'Zhao', 'year': '2022', 'journal-title': 'Emerg. Microb. Infect.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib68', 'doi-asserted-by': 'crossref', 'first-page': '134', 'DOI': '10.1038/s41392-021-00558-8', 'article-title': 'Cathepsin L plays a key role in SARS-CoV-2 infection in humans and ' 'humanized mice and is a promising target for new drug development', 'volume': '6', 'author': 'Zhao', 'year': '2021', 'journal-title': 'Signal Transduct. Targeted Ther.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib69', 'doi-asserted-by': 'crossref', 'first-page': '9218', 'DOI': '10.1074/jbc.M116.716100', 'article-title': 'Glycopeptide antibiotics potently inhibit cathepsin l in the late ' 'endosome/lysosome and block the entry of ebola virus, middle east ' 'respiratory syndrome coronavirus (MERS-CoV), and severe acute ' 'respiratory syndrome coronavirus (SARS-CoV)', 'volume': '291', 'author': 'Zhou', 'year': '2016', 'journal-title': 'J. Biol. Chem.'}, { 'key': '10.1016/j.antiviral.2023.105655_bib70', 'doi-asserted-by': 'crossref', 'first-page': '76', 'DOI': '10.1016/j.antiviral.2015.01.011', 'article-title': 'Protease inhibitors targeting coronavirus and filovirus entry', 'volume': '116', 'author': 'Zhou', 'year': '2015', 'journal-title': 'Antivir. Res.'}], 'container-title': 'Antiviral Research', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://api.elsevier.com/content/article/PII:S016635422300133X?httpAccept=text/xml', 'content-type': 'text/xml', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://api.elsevier.com/content/article/PII:S016635422300133X?httpAccept=text/plain', 'content-type': 'text/plain', 'content-version': 'vor', 'intended-application': 'text-mining'}], 'deposited': { 'date-parts': [[2023, 6, 23]], 'date-time': '2023-06-23T05:09:32Z', 'timestamp': 1687496972000}, 'score': 1, 'resource': {'primary': {'URL': 'https://linkinghub.elsevier.com/retrieve/pii/S016635422300133X'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2023, 6]]}, 'references-count': 69, 'alternative-id': ['S016635422300133X'], 'URL': 'http://dx.doi.org/10.1016/j.antiviral.2023.105655', 'relation': {}, 'ISSN': ['0166-3542'], 'subject': ['Virology', 'Pharmacology'], 'container-title-short': 'Antiviral Research', 'published': {'date-parts': [[2023, 6]]}, 'assertion': [ {'value': 'Elsevier', 'name': 'publisher', 'label': 'This article is maintained by'}, { 'value': 'Cathepsin inhibitors nitroxoline and its derivatives inhibit SARS-CoV-2 ' 'infection', 'name': 'articletitle', 'label': 'Article Title'}, {'value': 'Antiviral Research', 'name': 'journaltitle', 'label': 'Journal Title'}, { 'value': 'https://doi.org/10.1016/j.antiviral.2023.105655', 'name': 'articlelink', 'label': 'CrossRef DOI link to publisher maintained version'}, {'value': 'article', 'name': 'content_type', 'label': 'Content Type'}, { 'value': '© 2023 Elsevier B.V. All rights reserved.', 'name': 'copyright', 'label': 'Copyright'}], 'article-number': '105655'}